MX2022006787A - Composiciones y metodos que comprenden un anticuerpo anti-cd47 en combinacion con un anticuerpo dirigido al tumor. - Google Patents

Composiciones y metodos que comprenden un anticuerpo anti-cd47 en combinacion con un anticuerpo dirigido al tumor.

Info

Publication number
MX2022006787A
MX2022006787A MX2022006787A MX2022006787A MX2022006787A MX 2022006787 A MX2022006787 A MX 2022006787A MX 2022006787 A MX2022006787 A MX 2022006787A MX 2022006787 A MX2022006787 A MX 2022006787A MX 2022006787 A MX2022006787 A MX 2022006787A
Authority
MX
Mexico
Prior art keywords
antibody
methods
compositions
combination
binds
Prior art date
Application number
MX2022006787A
Other languages
English (en)
Inventor
Heyue Zhou
Damien Bresson
Christophe Pedros
Original Assignee
Sorrento Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics Inc filed Critical Sorrento Therapeutics Inc
Publication of MX2022006787A publication Critical patent/MX2022006787A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente divulgación proporciona composiciones y métodos que comprenden un primer anticuerpo que comprende un anticuerpo anti-CD47 completamente humano y un segundo anticuerpo que comprende una porción Fc que se une a un receptor Fc¿ en una célula efectora. En varias modalidades, el anticuerpo anti-CD47 utilizado en los métodos y composiciones presenta un bajo nivel de unión a los glóbulos rojos y no induce la hemaglutinación incluso a altas concentraciones de anticuerpo. En algunas modalidades, el segundo anticuerpo comprende un anticuerpo dirigido a tumores que incluye un anticuerpo que se une a los antígenos CD20, PD-L1, CD38 o SLAMF7. La combinación del anticuerpo anti-CD47 completamente humano y el segundo anticuerpo puede disminuir la carga de cáncer en un sujeto.
MX2022006787A 2019-12-05 2020-12-04 Composiciones y metodos que comprenden un anticuerpo anti-cd47 en combinacion con un anticuerpo dirigido al tumor. MX2022006787A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962943926P 2019-12-05 2019-12-05
US202063030464P 2020-05-27 2020-05-27
US202063065927P 2020-08-14 2020-08-14
PCT/US2020/063243 WO2021113596A2 (en) 2019-12-05 2020-12-04 Compositions and methods comprising an anti-cd47 antibody in combination with a tumor targeting antibody

Publications (1)

Publication Number Publication Date
MX2022006787A true MX2022006787A (es) 2022-07-19

Family

ID=74141822

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006787A MX2022006787A (es) 2019-12-05 2020-12-04 Composiciones y metodos que comprenden un anticuerpo anti-cd47 en combinacion con un anticuerpo dirigido al tumor.

Country Status (11)

Country Link
US (1) US20210221886A1 (es)
EP (1) EP4069286A2 (es)
JP (1) JP2023505256A (es)
KR (1) KR20220110810A (es)
CN (1) CN115052620A (es)
AU (1) AU2020396548A1 (es)
CA (1) CA3160173A1 (es)
IL (1) IL293463A (es)
MX (1) MX2022006787A (es)
TW (1) TW202134280A (es)
WO (1) WO2021113596A2 (es)

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
SI2477648T1 (sl) * 2009-09-15 2022-09-30 The Board Of Trustees Of The Leland Stanford Junior University Sinergijska terapija proti CD47 za krvne rake
AU2013267161A1 (en) 2012-05-31 2014-11-20 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
TWI778518B (zh) * 2015-03-04 2022-09-21 美商索倫多醫療公司 結合cd47之抗體治療劑
US9951144B2 (en) 2015-04-08 2018-04-24 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD38
JP2018535692A (ja) * 2015-09-21 2018-12-06 エラスムス ユニバーシティ メディカル センターＥｒａｓｍｕｓ Ｕｎｉｖｅｒｓｉｔｙ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ 抗ｃｄ４７抗体及び使用方法
MX2019004691A (es) 2016-10-20 2019-12-09 I Mab Biopharma Us Ltd Anticuerpos monoclonales cd47 novedosos y sus usos.
EP4129336A1 (en) * 2018-02-12 2023-02-08 Forty Seven, Inc. Anti-cd47 agent-based treatment of cd20-positive cancer
CN112313250A (zh) 2018-06-20 2021-02-02 索伦托药业有限公司 结合cd38的变体抗体

Also Published As

Publication number Publication date
US20210221886A1 (en) 2021-07-22
WO2021113596A2 (en) 2021-06-10
IL293463A (en) 2022-07-01
KR20220110810A (ko) 2022-08-09
AU2020396548A1 (en) 2022-07-14
TW202134280A (zh) 2021-09-16
CN115052620A (zh) 2022-09-13
CA3160173A1 (en) 2021-06-10
EP4069286A2 (en) 2022-10-12
WO2021113596A3 (en) 2021-08-12
JP2023505256A (ja) 2023-02-08

Similar Documents

Publication Publication Date Title
CL2022002448A1 (es) Constructos de anticuerpo para flt3 y cd3 (divisional sol.: 201800269)
EA202092945A1 (ru) Различные антигенсвязывающие домены, новые платформы и другие улучшения для клеточной терапии
PH12019502484A1 (en) Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
NZ750005A (en) Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof
BR112019014615A2 (pt) Receptores de antígeno quimérico contra axl ou ror2 e métodos de uso dos mesmos
MX2019010972A (es) Receptores de linfocito t (tcr) específicos del antígeno asociado a melanoma 1 (mage-a1) de alta afinidad y usos de estos.
MY196756A (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
BR112017019785A2 (pt) anticorpos terapêuticos e seus usos
WO2020113194A3 (en) Methods for treatment using adoptive cell therapy
NZ731633A (en) Antibodies against cd73 and uses thereof
WO2014008206A3 (en) DIAGNOSTIC AND THERAPEUTIC POTENTIAL OF HLA-E MONOSPECIFIC MONOCLONAL IgG ANTIBODIES DIRECTED AGAINST TUMOR CELL SURFACE AND SOLUBLE HLA-E
MX2021015888A (es) Fusión de un anticuerpo que se une a cea y 4-1bbl.
MX2021006681A (es) Anticuerpos anti-claudina y usos de los mismos.
EP2210939A4 (en) ANTIBODY ANTI-BST2
WO2019112978A3 (en) Anti-dclk1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof
PL422231A1 (pl) Komórki immunologiczne CAR do leczenia nowotworów
WO2016022939A8 (en) Human monoclonal antibodies specific for 5t4 and methods of their use
MX2020008718A (es) Anticuerpos de union a bcma y usos de los mismos.
MX2009010269A (es) Metodos de tratamiento del cancer mediante administracion de combinaciones de interleucina-18 humana.
MX2020008730A (es) Regímenes de dosificación de anticuerpo b7-h4.
WO2017177217A3 (en) Chimeric receptors and uses thereof in immune therapy
WO2017137595A3 (en) Cancer treatment using nk cells
IN2014CN04690A (es)
MX2022006787A (es) Composiciones y metodos que comprenden un anticuerpo anti-cd47 en combinacion con un anticuerpo dirigido al tumor.
MX2022007779A (es) Tratamiento que involucra celulas efectoras inmunitarias modificadas geneticamente para expresar receptores de antigenos.